Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT06208878
Enrolling by invitation Observational

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

NCT06208878 · tracked via the Priya Life Science USA tracker
Sponsor
CRISPR Therapeutics AG
Phase
Observational
Started
2023-11-22
Last updated
2026-09-24

Condition(s) studied

Hematologic MalignancySolid Malignancy

Investigational drug(s) / intervention(s)

Non Interventional

Non Interventional: Safety and Efficacy Assessment

Study summary

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document. * Must have received CRISPR CAR T cellular therapy. Exclusion Criteria: * There are no specific exclusion criteria.

Primary outcome measure(s)

  • The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment. — 15 years
    The number and percentage of subjects with CRISPR CAR T cellular therapy related SAEs and AESIs will be summarized.

Trial sites (24)

FacilityCityRegionStatus
City of Hope Duarte California
Cedars Sinai Los Angeles California
Stanford Stanford California
Yale New Haven Hospital New Haven Connecticut
Emory Atlanta Georgia
University of Chicago Chicago Illinois
University of Kansas Westwood Kansas
University of Minnesota Minneapolis Minnesota
Washington University Saint Louis St Louis Missouri
MSKCC New York New York
Montefiore Medical Center The Bronx New York
Oregon Health and Science University Portland Oregon
University of Pennsylvania Philadelphia Pennsylvania
UT Southwestern Dallas Texas
MD Anderson Cancer Center Houston Texas
Methodist Hospital-Sarah Cannon San Antonio Texas
University of Utah-Huntsman Cancer Institute Salt Lake City Utah
Royal Prince Alfred Hospital Camperdown New South Wales
Peter MacCallum Cancer Center Melbourne Victoria
Alfred Health Melbourne Australia
Sir Charles Gairdner Nedlands Australia
Epworth Healthcare Richmond Australia
Princess Margaret Toronto Ontario
University Hospital Hamburg-Eppendorf Hamburg Germany

More CRISPR Therapeutics AG trials in the USA

A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias Recruiting
A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension Recruiting
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies Recruiting
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease Recruiting

Other trials for the same condition

AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens) Enrolling by invitation
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib Recruiting
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) Recruiting
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06208878 on ClinicalTrials.gov ↗ ← All trials in the USA